Literature DB >> 6733000

Influence of chronic dosing on theophylline clearance.

H Efthimiou, D J Morgan, L Ioannides-Demos, K Raymond, A J McLean.   

Abstract

Theophylline clearance was studied in normal healthy volunteers before and after chronic oral dosing. Oral theophylline clearance showed a significant decrease (P less than 0.001) from 59.3 +/- 6.48 ml/min (mean +/- s.e. mean, n = 10) to 48.0 +/- 6.4 ml/min. Steady-state intravenous clearance decreased by 26 +/- 2% from 55.1 +/- 7.7 ml/min to 41.0 +/- 5.96 ml/min (mean +/- s.e. mean, n = 6; P less than 0.001) at constant steady-state intravenous test concentrations (mean 15.0 +/- 1.6 micrograms/ml after chronic oral dosing), excluding significant concentration dependence. Extrapolation of acute clearance findings to maintenance requirement may not be valid even in the same individual, with theophylline therapy requiring on-going review beyond acute stabilisation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6733000      PMCID: PMC1463460          DOI: 10.1111/j.1365-2125.1984.tb02385.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  Dose-dependent kinetics of theophylline disposition in asthmatic children.

Authors:  M Weinberger; E Ginchansky
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

2.  Renal clearance of theophylline in man.

Authors:  G Levy; R Koysooko
Journal:  J Clin Pharmacol       Date:  1976-07       Impact factor: 3.126

Review 3.  Monitoring serum theophylline levels.

Authors:  L Hendeles; M Weinberger; G Johnson
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

4.  Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline.

Authors:  J W Jenne; M S Wyze; F S Rood; F M MacDonald
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

5.  Pharmacokinetics of a microcrystalline theophylline preparation in patients with chronic obstructive airways disease.

Authors:  R K Elwood; J G Kelly; D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1978-03-17       Impact factor: 2.953

6.  Plasma theophylline level and ventilatory function in chronic obstructive pulmonary disease during prolonged oral treatment with choline theophyllinate.

Authors:  K B Bülow; H Larsson; T Leideman
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

7.  Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia.

Authors:  J R Powell; S Vozeh; P Hopewell; J Costello; L B Sheiner; S Riegelman
Journal:  Am Rev Respir Dis       Date:  1978-08

8.  Aminophylline bioavailability and the across-time stability of plasma theophylline levels.

Authors:  M Loren; D R Miklich; H Chai; G Barwise
Journal:  J Pediatr       Date:  1977-03       Impact factor: 4.406

9.  Simplified micro-scale procedure for preparing samples for theophylline determination by liquid chromatography.

Authors:  J W Nelson; A L Cordry; C G Aron; R A Bartell
Journal:  Clin Chem       Date:  1977-01       Impact factor: 8.327

10.  Theophylline bioavailability following chronic dosing of an elixir and two solid dosage forms.

Authors:  D D Shen; M Fixley; D L Azarnoff
Journal:  J Pharm Sci       Date:  1978-07       Impact factor: 3.534

View more
  4 in total

1.  Influence of chronic dosing on theophylline clearance.

Authors:  S Vozeh; F Follath
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

2.  Influence of chronic dosing on theophylline clearance.

Authors:  D J Morgan; K Raymond; A J McLean
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

Review 3.  Theophylline. Pooled Michaelis-Menten parameters (Vmax and Km) and implications.

Authors:  J G Wagner
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

4.  Comparison of single and multiple dose pharmacokinetics of theophylline using stable isotopes.

Authors:  R E Vestal; K E Thummel; G D Mercer; J R Koup
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.